Answer given by Mr Dalli on behalf of the Commission
Under the recently adopted breach of trust rules applicable to the members of scientific committees and experts of the European Medicines Agency, the decision on whether to launch the breach of trust procedure lies with the Executive Director of the Agency. The Commission requested the Agency to clarify whether it intends to launch the procedure against the former Chair of the Committee for Medicinal Products for Human Use in order to be able to reply to the question put forward by the Honourable Members. The Agency has informed the Commission that on the basis of the information currently available, it does not intend to launch the procedure in this particular case. However, should information subsequently become available that would warrant the launch of the breach of trust procedure, the Executive Director may decide to initiate checks that can be targeted to the issues that have been identified.